# Efficacy and Tolerability of Zolmitriptan Nasal Spray

> **NCT00617747** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2114 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Zolmitriptan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00617747
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** —
- **Final completion:** 2003-06
- **Target enrollment:** 2114 (ACTUAL)
- **Last updated:** 2009-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00617747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00617747, "Efficacy and Tolerability of Zolmitriptan Nasal Spray". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00617747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*